Desmoid tumors

By Sudha Thakor

Desmoid tumors, also known as aggressive fibromatosis, are rare fibroblastic neoplasms that present a significant therapeutic challenge.¹ Although benign and non-metastasizing, these tumors can behave aggressively at the local level, infiltrating surrounding structures and causing morbidity.^2,3 Their variable clinical course, ranging from indolent stability to persistent progression, requires nuanced, individualized management.^2,3

Advances in molecular understanding and a growing emphasis on quality of life have reshaped treatment goals.⁴ Active surveillance is increasingly prioritized over surgery for certain tumor types, recognizing that intervention itself can carry lasting consequences.⁵

What are the symptoms of desmoid tumors?

Symptoms vary according to tumor location, size, and growth rate. Patients may present with a painless, palpable mass or experience pain, stiffness, or restricted movement because of local tissue infiltration.⁶ Intra-abdominal tumors may cause bowel obstruction or ischemia, while extra abdominal disease can lead to nerve compression or lymphatic obstruction, causing pain or tingling sensations.⁷

How are desmoid tumors diagnosed?

Following a physical exam, desmoids are diagnosed via imaging tests, such as a CT scan or MRI, to define tumor extent and assess involvement of surrounding structures. A core needle biopsy provides histologic confirmation.⁶

What are the treatments for desmoid tumors?

First-line active surveillance is preferred for patients with asymptomatic or minimally symptomatic disease.^5,6 This strategy reflects evidence that desmoid tumors may remain stable or regress without treatment, avoiding unnecessary morbidity.^5,6

For progressive or symptomatic disease, systemic therapy is central to management.⁶ Options include tyrosine kinase inhibitors and cytotoxic chemotherapy, with surgery or radiotherapy reserved for selected cases where potential benefits outweigh functional risk.⁶

Are desmoid tumors associated with genetic syndromes?

Yes. A subset of cases occur in patients with familial adenomatous polyposis because of germline APC mutations,⁸ with patients often presenting with intra‑abdominal disease and a more aggressive course.⁹ 

References

1. Ibrahim, 2024. Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives. https://www.doi.org/10.1016/j.ctrv.2023.102675
2. Bektas, 2023. Desmoid tumors: A comprehensive review. https://www.doi.org/10.1007/s12325-023-02592-0
3. Samip, 2024. Desmoid tumor. https://www.ncbi.nlm.nih.gov/books/NBK459231/
4. Mangla, 2024. Desmoid tumors: Current perspective and treatment. https://www.doi.org/10.1007/s11864-024-01177-5
5. Wagner, 2025. 5 facts about surgery for desmoid tumors. https://www.mydesmoidtumorteam.com/resources/facts-about-surgery-for-desmoid-tumors
6. Cleveland Clinic, 2025. Desmoid tumors. https://my.clevelandclinic.org/health/diseases/22075-desmoid-tumors
7. Venkat, 2010. Abdominal pain and colonic obstruction from an intra-abdominal desmoid tumor. https://pmc.ncbi.nlm.nih.gov/articles/PMC2978418/
8. De Marchis, 2017. Desmoid tumors in familial adenomatous polyposis. https://pubmed.ncbi.nlm.nih.gov/28668823/
9. Yang and Ding, 2023. Update on familial adenomatous polyposis-associated desmoid tumors. https://www.doi.org/10.1055/s-0043-1767709

Developed by EPG Health for Medthority, independently of any sponsor.